Search This Blog

Thursday, June 30, 2022

Immunome Starts Phase 1b Study of IMM-BCP-01 for COVID-19

 

  • First study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients

  • Study will evaluate safety as the primary end point with pharmacokinetics (PK) and virology as secondary assessments

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)